Last reviewed · How we verify

Amoxicillin (ST14) — Competitive Intelligence Brief

Amoxicillin (ST14) (Amoxicillin (ST14)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic. Area: Infectious Disease.

marketed Beta-lactam antibiotic Penicillin-binding proteins (PBPs) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Amoxicillin (ST14) (Amoxicillin (ST14)) — National Taiwan University Hospital. Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking peptidoglycan cross-linking.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Amoxicillin (ST14) TARGET Amoxicillin (ST14) National Taiwan University Hospital marketed Beta-lactam antibiotic Penicillin-binding proteins (PBPs)
Amoxil amoxicillin Generic (originally Beecham/GSK) marketed Aminopenicillin (Beta-lactam antibiotic) 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C 1972-01-01
Bicillin C-R Penicillin G Benzathine Pfizer marketed Beta-lactam antibiotic Cell-wall peptidoglycan biosynthesis 1952-01-01
Bicillin C-R Penicillin G Benzathine Pfizer marketed Beta-lactam antibiotic Cell-wall peptidoglycan biosynthesis 1952-01-01
Cefazolin and indomethacin Cefazolin and indomethacin Thomas Jefferson University marketed Beta-lactam antibiotic + NSAID combination Bacterial penicillin-binding proteins (cefazolin); COX-1 and COX-2 (indomethacin)
Rabeprazloe+bismuth+amoxicillin+clarithromycin Rabeprazloe+bismuth+amoxicillin+clarithromycin Xijing Hospital of Digestive Diseases marketed Proton pump inhibitor + bismuth salt + beta-lactam antibiotic + macrolide antibiotic combination H+ ATPase (rabeprazole); H. pylori urease and cell wall (bismuth); bacterial peptidoglycan (amoxicillin); bacterial ribosome (clarithromycin)
Fosfomycin and imipenem Fosfomycin and imipenem Juan A. Arnaiz marketed Beta-lactam antibiotic combination Bacterial cell wall synthesis (MurA enzyme and penicillin-binding proteins)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Beta-lactam antibiotic class)

  1. Pfizer · 2 drugs in this class
  2. Bayer · 1 drug in this class
  3. Belén Retamal-Valdes · 1 drug in this class
  4. Benova (Tianjin) Innovative medicine Research Co., Ltd. · 1 drug in this class
  5. Esraa Salah Mohamed Abdallah Eladl · 1 drug in this class
  6. Incheon St.Mary's Hospital · 1 drug in this class
  7. International Maternal Pediatric Adolescent AIDS Clinical Trials Group · 1 drug in this class
  8. KEMRI-Wellcome Trust Collaborative Research Program · 1 drug in this class
  9. National Taiwan University Hospital · 1 drug in this class
  10. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Amoxicillin (ST14) — Competitive Intelligence Brief. https://druglandscape.com/ci/amoxicillin-st14. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: